Terapevticheskii arkhivTerapevticheskii arkhiv0040-36602309-5342LLC Obyedinennaya Redaktsiya3364010.26442/00403660.2019.08.000381Research ArticleSorafenib - induced thyroiditis in patient with a relapse of acute myelomonocytic leukemia with FLT3-ITD mutationBalzhanovaYa B-ParovichnikovaE N-SokolovA N-RyzhkoV V-SamtsovaM A-GribanovaE O-National Research Center for Hematology15082019918939716042020Copyright © 2019, Consilium Medicum2019Sorafenib has been used in acute myeloid leukemias with FLT3-ITD mutation improving the outcomes. However the high incidence of treatment - emergent adverse event may be associated with treatment using sorafenib with cytotoxic chemotherapy. We have reported a case of severe thyroiditis in patient with a relapse of acute myelomonocytic leukemia.sorafenibthyroiditisacute myeloid leukemiarelapseFLT3-ITD mutationсорафенибтиреоидитострый миелоидный лейкозрецидивмутация FLT3-ITD[O’Donnell M.R, Tallman M.S, Abboud C.N, Altman J.K, Appelbaum F.R, Arber D.A, Bhatt V, Bixby D, Blum W, Coutre S.E, de Lima M, Fathi A.T, Fiorella M, Foran J.M, Gore S.D, Hall A.C, Kropf P, Lancet J, Maness L.J, Marcucci G. Acute myeloid leukemia, version 3.2017, NCCN clinical practice guidelines in oncology. J Nat Comprehens Cancer Network. 2017;15(7):926-57. doi: 10.6004/jnccn.2017.0116][Gu T, Nardone J, Wang Y, Loriaux M, Villén J, Beausoleil S, Tucker M, Kornhauser J, Ren J, Mac Neill J, Gygi S, Druker B, Heinrich M, Rush J, Polakiewicz R. Survey of activated FLT3 signaling in leukemia. PLoS One. 2011;6(4):e19169. doi: 10.1371/journal.pone.0019169][Shih L.Y, Huang C.F, Wu J.H, Lin T.L, Dunn P, Wang P.N, Kuo M.C, Lai C.L, Hsu H.C. Internal tandem duplication of FLT3 in relapsed acute myeloid leukemia: a comparative analysis of bone marrow samples from 108 adult patients at diagnosis and relapse. Blood. 2002;100(7):2387-92. doi: 10.1182/blood-2002-01-0195][Nazha A, Cortes J, Faderl S, Pierce S, Daver N, Kadia T, Borthakur G, Luthra R, Kantarjian H, Ravandi F. Activating internal tandem duplication mutations of the fms - like tyrosine kinase-3 (FLT3-ITD) at complete response and relapse in patients with acute myeloid leukemia. Haematologica. 2012;97(8):1242-5. doi: 10.3324/haematol.2012.062638][Stone R.M, Mandrekar S.J, Sanford B.L, Laumann K, Geyer S, Bloomfield C.D, Thiede C, Prior T.W, Döhner K, Marcucci G, Lo-Coco F, Klisovic R.B, Wei A, Sierra J, Sanz M.A, Brandwein J.M, de Witte T, Niederwieser D, Appelbaum F.R, Medeiros B.C, Tallman M.S, Krauter J, Schlenk R.F, Ganser A, Serve H, Ehninger G, Amadori S, Larson R.A, Döhner H. Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation. N Engl J Med. 2017;377(5):454-64. doi: 10.1056/NEJMoa1614359][Altman J.K, Foran J.M, Pratz K.W, Trone D, Cortes J.E, Tallman M.S. Phase 1 study of quizartinib in combination with induction and consolidation chemotherapy in patients with newly diagnosed acute myeloid leukemia. Am J Hematol. 2018;93(2):213-21. doi: 10.1002/ajh.24974][Румянцев П.О. Роль таргетной терапии мультикиназными ингибиторами в лечении резистентного к радиойодтерапии дифференцированного рака щитовидной железы. Клиническая и экспериментальная тиреоидология. 2015;11(2):25-32. doi: 10.14341/ket2015225-32][Al-Kali A, Cortes J, Faderl S, Jones D, Abril C, Pierce S, Brandt M, Kantarjian H, Ravandi F. Patterns of molecular response to and relapse after combination of sorafenib, idarubicin, and cytarabine in patients with FLT3 mutant acute myeloid leukemia. Clin Lymph Myel Leuk. 2011;11(4):361-6. doi: 10.1016/j.clml.2011.06.007][Uy G.L, Mandrekar S.J, Laumann K, Marcucci G, Zhao W, Levis M.J, Klepin H.D, Baer M.R, Powell B.L, Westervelt P, de Angelo D.J, Stock W, Sanford B, Blum W.G, Bloomfield C.D, Stone R.M, Larson R.A. A phase 2 study incorporating sorafenib into the chemotherapy for older adults with FLT3-mutated acute myeloid leukemia: CALGB 11001. Blood Advanc. 2017;1(5):331-40. doi: 10.1182/bloodadvances.2016003053][Röllig C, Serve H, Hüttmann A, Noppeney R, Müller-Tidow C, Krug U, Baldus C.D, Brandts C.H, Kunzmann V, Einsele H, Krämer A, Schäfer-Eckart K, Neubauer A, Burchert A, Giagounidis A, Krause S.W, Mackensen A, Aulitzky W, Herbst R, Hänel M, Kiani A, Frickhofen N, Kullmer J, Kaiser U, Link H, Geer T, Reichle A, Junghan C, Repp R, Heits F, Dürk H, Hase J, Klut IM, Illmer T, Bornhäuser M, Schaich M, Parmentier S, Görner M, Thiede C, von Bonin M, Schetelig J, Kramer M, Berdel W.E, Ehninger G. Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial. Lancet Oncol. 2015;16(16):1691-9. doi: 10.1016/S1470-2045(15)00362-9][Randrup Hansen C, Grimm D, Bauer J, Wehland M, Magnusson N.E. Effects and side effects of using sorafenib and sunitinib in the treatment of metastatic renal cell carcinoma. Int J Mol Sci. 2017;18(2):461. doi: 10.3390/ijms18020461][Юсупова Р.А., Подольская Т.Б. Ультразвуковое исследование аутоиммунного тиреоидита в амбулаторных условиях. Практическая медицина. 2017;(2):130-3.][Fallahi P, Ferrari S.M, Vita R, Di Domenicantonio A, Corrado A, Benvenga S, Antonelli A. Thyroid dysfunctions induced by tyrosine kinase inhibitors. Exp Opin Drug Saf. 2014;13(6):723-33. doi: 10.1517/14740338.2014.913021][Van Doorn L, Eskens F.A, Visser T.J, van der Lugt A, Mathijssen R.H, Peeters R.P. Sorafenib induced thyroiditis in two patients with hepatocellular carcinoma. Thyroid. 2011;21(2):197-202. doi: 10.1089/thy.2010.0234][Takahashi H, Nasu K, Minami M, Kojima T, Nishiyama H, Ishiguro T, Konishi T. Organ atrophy Induced by sorafenib and sunitinib - quantitative computed tomography (CT) evaluation of the pancreas, thyroid gland and spleen. Pol J Radiol. 2016;81:557. doi: 10.12659/PJR.898936][Iavarone M, Perrino M, Viganò M, Beck-Peccoz P, Fugazzola L. Sorafenib - induced destructive thyroiditis. Thyroid. 2010;20(9):1043-4. doi: 10.1089/thy.2010.0070 PMID:20825302][Sun J, Hu J, Huang Y, Ying S.W, Han X.Y, Zheng Y.L, Huang H. Sorafenib - induced thyroiditis in FMS-like tyrosine kinase 3-internal tandem duplication - mutated acute myeloid leukemia. Chin Med J. 2016;129(20):2512. doi: 10.4103/0366-6999.191831][Mooij C.F, Netea-Maier R.T, ten Broek R, Gotthardt M, Hagleitner M.M. Pancytopenia and hypothyroidism in a patient with leukemic infiltration of the thyroid as the first presentation of acute lymphoblastic leukemia. J Ped Hematol Oncol. 2018;40(2):145-7. doi: 10.1097/MPH.0000000000000869][Sen R, Gupta S, Batra A, Gill M, Gupta V, Marwah N. Acute lymphoblastic leukaemia (ALL) with infiltration of the thyroid: a cytological diagnosis. Endocr Pathol. 2012;23(4):268-9. doi: 10.1007/s12022-012-9206-y]